NK cell recognition

Annual Review of Immunology

Volumn 23, Issue , 2005, Pages 225-274

  Lanier, Lewis L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Immune receptors; Innate immunity; Signal transduction

Indexed keywords

CD94 ANTIGEN; CELL SURFACE RECEPTOR; IMMUNOGLOBULIN RECEPTOR; KILLER CELL ACTIVATING RECEPTOR ASSOCIATED PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN; PROTEIN 2B4; PROTEIN DNAM 1; PROTEIN NK1.1; PROTEIN PILR; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; EFFECTOR CELL; HUMAN; HYPOTHESIS; IMMUNE RESPONSE; IMMUNE SYSTEM; INNATE IMMUNITY; LEUKOCYTE FUNCTION; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNITY, NATURAL; KILLER CELLS; KILLER CELLS, NATURAL; LIGANDS; MICE; MODELS, IMMUNOLOGICAL; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION;

EID: 11144299492     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.23.021704.115526     Document Type: Review

References (352)

1. Spits H, Blom B, Jaleco AC, Weijer K, Verschuren MC, et al. 1998. Early stages in the development of human T, natural killer and thymic dendritic cells. Immunol. Rev. 165:75-86
2. Colucci F, Caligiuri MA, Di Santo JP. 2003. What does it take to make a natural killer? Nat. Rev. Immunol. 3:413-25
3. Davis DM, Chiu I, Fassett M, Cohen GB, Mandelboim O, Strominger JL. 1999. The human natural killer cell immune synapse. Proc. Natl. Acad. Sci. USA 96:15062-67
4. Lou Z, Jevremovic D, Billadeau DD, Leibson PJ. 2000. A balance between positive and negative signals in cytotoxic lymphocytes regulates the polarization of lipid rafts during the development of cell-mediated killing. J. Exp. Med. 19:347-54
5. Vyas YM, Mehta KM, Morgan M, Maniar H, Butros L, et al. 2001. Spatial organization of signal transduction molecules in the NK cell immune synapses during MHC class I-regulated noncytolytic and cytolytic interactions. J. Immunol. 167:4358-67
6. Vyas YM, Maniar H, Dupont B. 2002. Cutting edge: Differential segregation of the SRC homology 2-containing protein tyrosine phosphatase-1 within the early NK cell immune synapse distinguishes noncytolytic from cytolytic interactions. J. Immunol. 168:3150-54
7. Orange JS, Harris KE, Andzelm MM, Valter MM, Geha RS, Strominger JL. 2003. The mature activating natural killer cell immunologic synapse is formed in distinct stages. Proc. Natl. Acad. Sci. USA 100:14151-56
8. Stetson DB, Mohrs M, Reinhardt RL, Baron JL, Wang ZE, et al. 2003. Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J. Exp. Med. 198:1069-76
9. Vivier E, Anfossi N. 2004. Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future. Nat. Rev. Immunol. 4:190-98
10. Karre K, Ljunggren HG, Piontek G, Kiessling R. 1986. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defense strategy. Nature 319:675-78
11. 2m- bone marrow in chimeric mice. Proc. Natl. Acad. Sci. USA 88:10332-36
12. Bix M, Liao N-S, Zijlstra M, Loring J, Jaenisch R, Raulet D. 1991. Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice. Nature 349:329-31
13. Ljunggren H-G, Karre K. 1990. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol. Today 11:237-44
14. Lanier LL, Corliss B, Phillips JH. 1997. Arousal and inhibition of human NK cells. Immunol. Rev. 155:145-54
15. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. 2001. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413:165-71
16. Cerwenka A, Baron JL, Lanier LL. 2001. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. USA 98:11521-26
17. Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP. 2000. Role of CD47 as a marker of self on red blood cells. Science 288:2051-54
18. Carlyle JR, Jamieson AM, Gasser S, Clingan CS, Arase H, Raulet DH. 2004. Missing self-recognition of Ocil/Clr-b by inhibitory NKR-P1 natural killer cell receptors. Proc. Natl. Acad. Sci. USA 101:3527-32
19. Iizuka K, Naidenko OV, Plougastel BF, Fremont DH, Yokoyama WM. 2003. Genetically linked C-type lectin-related ligands for the NKRP1 family of natural killer cell receptors. Nat. Immunol. 4:801-7
20. Meyaard L, Adema GJ, Chang C, Woollatt E, Sutherland GR, et al. 1997. LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. Immunity 7:283-90
21. Poggi A, Tomasello E, Revello V, Nanni L, Costa P, Moretta L. 1997. p40 molecule regulates NK cell activation mediated by NK receptors for HLA class I antigens and TCR-mediated triggering of T lymphocytes. Int. Immunol. 9:1271-79
22. Butcher S, Arney KL, Cook GP. 1998. MAFA-L, an ITIM-containing receptor encoded by the human NK cell gene complex and expressed by basophils and NK cells. Eur. J. Immunol. 28:3755-62
23. Hanke T, Corral L, Vance RE, Raulet DH. 1998. 2F1 antigen, the mouse homolog of the rat "mast cell function-associated antigen", is a lectin-like type II transmembrane receptor expressed by natural killer cells. Eur. J. Immunol. 28:4409-17
24. Rojo S, Burshtyn DN, Long EO, Wagtmann N. 1997. Type I transmembrane receptor with inhibitory function in mouse mast cells and NK cells. J. Immunol. 158:9-12
25. Wang LL, Mehta IK, LeBlanc PA, Yokoyama WM. 1997. Mouse natural killer cells express gp49B1, a structural homologue of human killer inhibitory receptors. J. Immunol. 158:13-17
26. Castells MC, Klickstein LB, Hassani K, Cumplido JA, Lacouture ME, et al. 2001. gp49B1-α(v)β3 interaction inhibits antigen-induced mast cell activation. Nat. Immunol. 2:436-42
27. Gu X, Laouar A, Wan J, Daheshia M, Lieberman J, et al. 2003. The gp49B1 inhibitory receptor regulates the IFN-γ responses of T cells and NK cells. J. Immunol. 170:4095-101
28. Moller MJ, Kammerer R, Grunert F, von Kliest S. 1996. Biliary glycoprotein (BGP) expression on T cells and on a natural killer cell subpopulation. Int. J. Cancer 65:740-45
29. Markel G, Lieberman N, Katz G, Arnon TI, Lotem M, et al. 2002. CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity. J. Immunol. 168:2803-10
30. Nicoll G, Ni J, Liu D, Klenerman P, Munday J, et al. 1999. Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes. J. Biol. Chem. 274:34089-95
31. Nicoll G, Avril T, Lock K, Furukawa K, Bovin N, Crocker PR. 2003. Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec-7-dependent and -independent mechanisms. Eur. J. Immunol. 33:1642-48
32. Muta T, Kurosaki T, Misulovin Z, Sanchez M, Nussenzweig MC, Ravetc̄h RV. 1994. A 13-amino acid motif in the cytoplasmic domain of FcγRIIB modulates B-cell receptor signalling. Nature 368:70-73
33. Ravetch JV, Lanier LL. 2000. Immune inhibitory receptors. Science 290:84-89
34. Valiante NM, Phillips JH, Lanier LL, Parham P. 1996. Killer cell inhibitory receptor recognition of human leukocyte antigen (HLA) class I blocks formation of a pp36/PLC-γ signaling complex in human natural killer (NK) cells. J. Exp. Med. 184:2243-50
35. Binstadt BA, Brumbaugh KM, Dick CJ, Scharenberg AM, Williams BL, et al. 1996. Sequential involvement of Lck and SHP-1 with MHC-recognizing receptors on NK cells inhibits FcR-initiated tyrosine kinase activation. Immunity 5:629-38
36. Binstadt BA, Billadeau DD, Jevremovic D, Williams BL, Fang N, et al. 1998. SLP-76 is a direct substrate of SHP-1 recruited to killer cell inhibitory receptors. J. Biol. Chem. 273:27518-23
37. Palmieri G, Tullio V, Zingoni A, Piccoli M, Frati L, et al. 1999. CD94/NKG2-A inhibitory complex blocks CD16-triggered syk and extracellular regulated kinase activation, leading to cytotoxic function of human NK cells. J. Immunol. 162:7181-88
38. Stebbins CC, Watzl C, Billadeau DD, Leibson PJ, Burshtyn DN, Long EO. 2003. Vav1 dephosphorylation by the tyrosine phosphatase SHP-1 as a mechanism for inhibition of cellular cytotoxicity. Mol. Cell Biol. 23:6291-99
39. Reth M. 1989. Antigen receptor tail clue. Nature 338:383-84
40. Hibbs ML, Selvaraj P, Carpen O, Springer TA, Kuster H, et al. 1989. Mechanisms for regulating expression of membrane isoforms of FcγRIII (CD16). Science 246:1608-11
41. Anderson P, Caligiuri M, Ritz J, Schlossman SF. 1989. CD3-negative natural killer cells express ζ TCR as part of a novel molecular complex. Nature 341:159-62
42. Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH. 1998. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 391:703-7
43. Olcese L, Cambiaggi A, Semenzato G, Bottino C, Moretta A, Vivier E. 1997. Human killer cell activatory receptors for MHC class I molecules are included in a multimeric complex expressed by Natural Killer cells. J. Immunol. 158:5083-86
44. Perussia B, Starr S, Abraham S, Fanning V, Trinchieri G. 1983. Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1. J. Immunol. 130:2133-41
45. Lanier LL, Le AM, Phillips JH, Warner NL, Babcock GF. 1983. Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. J. Immunol. 131:1789-96
46. Lanier LL. 1998. NK cell receptors. Annu. Rev. Immunol. 16:359-93
47. Ravetch JV, Holland S. 2001. IgG Fc receptors. Annu. Rev. Immunol. 19:275-90
48. Lanier LL, Yu G, Phillips JH. 1989. Co-association of CD3ζ with a receptor (CD16) for IgG Fc on human natural killer cells. Nature 342:803-5
49. Kurosaki T, Gander I, Ravetch JV. 1991. A subunit common to an IgG Fc receptor and the T-cell receptor mediates assembly through different interactions. Proc. Natl. Acad. Sci. USA 88:3837-41
50. Colucci F, Schweighoffer E, Tomasello E, Turner M, Ortaldo JR, et al. 2002. Natural cytotoxicity uncoupled from the Syk and ZAP-70 intracellular kinases. Nat. Immunol. 3:288-94
51. Zompi S, Hamerman JA, Ogasawara K, Schweighoffer E, Tybulewicz VL, et al. 2003. NKG2D triggers cytotoxicity in mouse NK cells lacking DAP12 or Syk family kinases. Nat. Immunol. 4:565-72
52. + IL-2-activated natural killer cells. Nature 358:66-70
53. Mehta IK, Wang J, Roland J, Margulies DH, Yokoyama WM. 2001. Ly49A allelic variation and MHC class I specificity. Immunogenetics 53:572-83
54. Wilhelm BT, Gagnier L, Mager DL. 2002. Sequence analysis of the ly49 cluster in C57BL/6 mice: a rapidly evolving multigene family in the immune system. Genomics 80:646-61
55. Makrigiannis AP, Pau AT, Saleh A, Winkler-Pickett R, Ortaldo JR, Anderson SK. 2001. Class I MHC-binding characteristics of the 129/J Ly49 repertoire. J. Immunol. 166:5034-43
56. Yokoyama WM, Plougastel BF. 2003. Immune functions encoded by the natural killer gene complex. Nat. Rev. Immunol. 3:304-16
57. Smith KM, Wu J, Bakker ABH, Phillips JH, Lanier LL. 1998. Cutting Edge: Ly49D and Ly49H associate with mouse DAP12 and form activating receptors. J. Immunol. 161:7-10
58. Bakker ABH, Hoek RM, Cerwenka A, Blom B, Lucian L, et al. 2000. DAP12-deficient mice fail to develop autoimmunity due to impaired antigen priming. Immunity 13:345-53
59. Kubota A, Kubota S, Lohwasser S, Mager DL, Takei F. 1999. Diversity of NK cell receptor repertoire in adult and neonatal mice. J. Immunol. 163:212-16
60. Held W, Roland J, Raulet DH. 1995. Allelic exclusion of Ly49-family genes encoding class I MHC-specific receptors on NK cells. Nature 376:355-58
61. Held W, Raulet DH. 1997. Expression of the Ly49A gene in murine natural killer cell clones is predominantly but not exclusively mono-allelic. Eur. J. Immunol. 27:2876-84
62. Saleh A, Davies GE, Pascal V, Wright PW, Hodge DL, et al. 2004. Identification of probabilistic transcriptional switches in the Ly49 gene cluster: a novel eukaryotic mechanism for selective gene activation. Immunity 21:1-20
63. Raulet DH, Vance RE, McMahon CW. 2001. Regulation of the natural killer cell receptor repertoire. Annu. Rev. Immunol. 19:291-330
64. Veinotte LL, Wilhelm BT, Mager DL, Takei F. 2003. Acquisition of MHC-specific receptors on murine natural killer cells. Crit. Rev. Immunol. 23:251-66
65. Mehta IK, Smith HR, Wang J, Margulies DH, Yokoyama WM. 2001. A "chimeric" C57L-derived Ly49 inhibitory receptor resembling the Ly49d activation receptor. Cell. Immunol. 209:29-41
66. Tormo J, Natarajan K, Margulies DH, Mariuzza RA. 1999. Crystal structure of a lectin-like natural killer cell receptor bound to its MHC class I ligand. Nature 402:623-31
67. Dam J, Guan R, Natarajan K, Dimasi N, Chlewicki LK, et al. 2003. Variable MHC class I engagement by Ly49 natural killer cell receptors demonstrated by the crystal structure of Ly49C bound to H-2K(b). Nat. Immunol. 4:1213-22
68. Natarajan K, Dimasi N, Wang J, Mariuzza RA, Margulies DH. 2002. Structure and function of natural killer cell receptors: multiple molecular solutions to self, non-self discrimination. Annu. Rev. Immunol. 20:853-85
69. Wang J, Whitman MC, Natarajan K, Tormo J, Mariuzza RA, Margulies DH. 2002. Binding of the natural killer cell inhibitory receptor Ly49A to its major histocompatibility complex class I ligand. Crucial contacts include both H-2Dd and β 2-microglobulin. J. Biol. Chem. 277:1433-42
70. Orihuela M, Margulies DH, Yokoyama WM. 1996. The NK cell receptor Ly-49A recognizes a peptide-induced conformational determinant on its MHC class I ligand. Proc. Natl. Acad. Sci. USA 93:11792-97
71. Correa I, Raulet DH. 1995. Binding of diverse peptides to MHC class I molecules inhibits target cell lysis by activated natural killer cells. Immunity 2:61-71
72. Hanke T, Takizawa H, McMahon CW, Busch DH, Pamer EG, et al. 1999. Direct assessment of MHC class I binding by seven Ly49 inhibitory NK cell receptors. Immunity 11:67-77
73. Michaelsson J, Achour A, Salcedo M, Kase-Sjostrom A, Sundback J, et al. 2000. Visualization of inhibitory Ly49 receptor specificity with soluble major histocompatibility complex class I tetramers. Eur. J. Immunol. 30:300-7
74. Doucey MA, Scarpellino L, Zimmer J, Guillaume P, Luescher IF, et al. 2004. Cis association of Ly49A with MHC class I restricts natural killer cell inhibition. Nat. Immunol. 5:328-36
75. George TC, Ortaldo JR, Lemieux S, Kumar V, Bennett M. 1999. Tolerance and alloreactivity of the Ly49D subset of murine NK cells. J. Immunol. 163:1859-67
76. George TC, Mason LH, Ortaldo JR, Kumar V, Bennett M. 1999. Positive recognition of MHC class I molecules by the Ly49D receptor of murine NK cells. J. Immunol. 162:2035-43
77. Nakamura MC, Linnemeyer PA, Niemi EC, Mason LH, Ortaldo JR, et al. 1999. Mouse Ly-49D recognizes H-2Dd and activates natural killer cell cytotoxicity. J. Exp. Med. 189:493-500
78. + NK cells with H-2Dd Target cells leads to Dap-12 phosphorylation and IFN-γ secretion. J. Immunol. 164:603-11
79. 2-microglobulin-deficient mice. J. Immunol. 169:126-36
80. Ortaldo JR, Bere EW, Hodge D, Young HA. 2001. Activating ly-49 NK receptors: central role in cytokine and chemokine production. J. Immunol. 166:4994-99
81. Silver ET, Gong D, Hazes B, Kane KP. 2001. Ly-49W, an activating receptor of nonobese diabetic mice with close homology to the inhibitory receptor Ly-49G, recognizes H-2D(k) and H-2D(d). J. Immunol. 166:2333-41
82. Silver ET, Gong DE, Chang CS, Amrani A, Santamaria P, Kane KP. 2000. Ly-49P activates NK-mediated lysis by recognizing H-2Dd. J. Immunol. 165:1771-81
83. Ortaldo JR, Young HA. 2003. Expression of TFN-γ upon triggering of activating Ly49D NK receptors in vitro and in vivo: costimulation with IL-12 or IL-18 overrides inhibitory receptors. J. Immunol. 170:1763-69
84. Brown MG, Dokun AO, Heusel JW, Smith HR, Beckman DL, et al. 2001. Vital involvement of a natural killer cell activation receptor in resistance to viral infection. Science 292:934-37
85. Daniels KA, Devora G, Lai WC, O'Donnell CL, Bennett M, Welsh RM. 2001. Murine cytomegalovirus is regulated by a discrete subset of natural killer cells reactive with monoclonal antibody to Ly49H. J. Exp. Med. 194:29-44
86. Lee SH, Zafer A, de Repentigny Y, Kothary R, Tremblay ML, et al. 2003. Transgenic expression of the activating natural killer receptor Ly49H confers resistance to cytomegalovirus in genetically susceptible mice. J. Exp. Med. 197:515-26
87. Sjolin H, Tomasello E, Mousavi-Jazi M, Bartolazzi A, Karre K, et al. 2002. Pivotal role of KARAP/DAP12 adaptor molecule in the natural killer cell-mediated resistance to murine cytomegalovirus infection. J. Exp. Med. 195:825-34
88. Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL. 2002. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 296:1323-26
89. Smith HR, Heusel JW, Mehta IK, Kim S, Dorner BG, et al. 2002. Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc. Natl. Acad. Sci. USA 99:8826-31
90. Bubi I, Wagner M, Krmpoti A, Saulig T, Kim S, et al. 2004. Gain of virulence caused by loss of a gene in murine cytomegalovirus. J. Virol. 78:7536-44
91. Voigt V, Forbes CA, Tonkin JN, Degli-Esposti MA, Smith HR, et al. 2003. Murine cytomegalovirus m157 mutation and variation leads to immune evasion of natural killer cells. Proc. Natl. Acad. Sci. USA 100:13483-88
92. French AR, Pingel JT, Wagner M, Bubic I, Yang L, et al. 2004. Escape of mutant double-stranded DNA virus from innate immune control. Immunity 20:747-56
93. Arase H, Lanier LL. 2004. Specific recognition of virus-infected cells by paired NK receptors. Rev. Med. Virol. 14:83-93
94. Westgaard IH, Berg SF, Orstavik S, Fossum S, Dissen E. 1998. Identification of a human member of the Ly-49 multigene family. Eur. J. Immunol. 28:1839-46
95. Barten R, Trowsdale J. 1999. The human Ly-49L gene. Immunogenetics 49:731-34
96. Mager DL, McQueen KL, Wee V, Freeman JD. 2001. Evolution of natural killer cell receptors. Coexistence of functional Ly49 and KIR genes in baboons. Curr. Biol. 11:626-30
97. Gagnier L, Wilhelm BT, Mager DL. 2003. Ly49 genes in non-rodent mammals. Immunogenetics 55:109-15
98. Guethlein LA, Flodin LR, Adams EJ, Parham P. 2002. NK cell receptors of the orangutan (Pongo pygmaeus): a pivotal species for tracking the coevolution of killer cell Ig-like receptors with MHC-C. J. Immunol. 169:220-29
99. Takahashi T, Yawata M, Raudsepp T, Lear TL, Chowdhary BP, et al. 2004. Natural killer cell receptors in the horse: evidence for the existence of multiple transcribed LY49 genes. Eur. J. Immunol. 34:773-84
100. Uhrberg M, Valiante NM, Shum BP, Shilling HG, Lienert-Weidenbach K, et al. 1997. Human diversity in killer cell inhibitory receptor (KIR) genes. Immunity 7:753-63
101. Vilches C, Parham P. 2002. KIR: Diverse, rapidly evolving receptors of innate and adaptive immunity. Annu. Rev. Immunol. 20:217-51
102. Maxwell LD, Wallace A, Middleton D, Curran MD. 2002. A common KIR2DS4 deletion variant in the human that predicts a soluble KIR molecule analogous to the KIR1D molecule observed in the rhesus monkey. Tissue Antigens 60:254-58
103. Hsu KC, Liu XR, Selvakumar A, Mickelson E, O'Reilly RJ, Dupont B. 2002. Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets. J. Immunol. 169:5118-29
104. Goodridge JP, Witt CS, Christiansen FT, Warren HS. 2003. KIR2DL4 (CD158d) genotype influences expression and function in NK cells. J. Immunol. 171:1768-74
105. Pando MJ, Gardiner CM, Gleimer M, McQueen KL, Parham P. 2003. The protein made from a common allele of KIR3DL1 (3DL1*004) is poorly expressed at cell surfaces due to substitution at positions 86 in Ig domain 0 and 182 in Ig domain 1. J. Immunol. 171:6640-49
106. Wilson MJ, Torkar M, Haude A, Milne S, Jones T, et al. 2000. Plasticity in the organization and sequences of human KIR/ILT gene families. Proc. Natl. Acad. Sci. USA 97:4778-83
107. Khakoo SI, Rajalingam R, Shum BP, Weidenbach K, Flodin L, et al. 2000. Rapid evolution of NK cell receptor systems demonstrated by comparison of chimpanzees and humans. Immunity 12:687-98
108. Rajalingam R, Parham P, Abi-Rached L. 2004. Domain shuffling has been the main mechanism forming new hominoid killer cell Ig-like receptors. J. Immunol. 172:356-69
109. Martin MP, Nelson G, Lee JH, Pellett F, Gao X, et al. 2002. Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J. Immunol. 169:2818-22
110. Martin AM, Kulski JK, Gaudieri S, Witt CS, Freitas EM, et al. 2004. Comparative genomic analysis, diversity and evolution of two KIR haplotypes A and B. Gene 335:121-31
111. Storset AK, Slettedal IO, Williams JL, Law A, Dissen E. 2003. Natural killer cell receptors in cattle: A bovine killer cell immunoglobulin-like receptor multigene family contains members with divergent signaling motifs. Eur. J. Immunol. 33:980-90
112. Hoelsbrekken SE, Nylenna O, Saether PC, Slettedal IO, Ryan JC, et al. 2003. Cutting edge: molecular cloning of a killer cell Ig-like receptor in the mouse and rat. J. Immunol. 170:2259-63
113. Welch AY, Kasahara M, Spain LM. 2003. Identification of the mouse killer immunoglobulin-like receptor-like (Kir1) gene family mapping to chromosome X. Immunogenetics 54:782-90
114. + natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition. J. Exp. Med. 172:1589-98
115. Litwin V, Gumperz J, Parham P, Phillips JH, Lanier LL. 1994. NKB1: An NK cell receptor involved in the recognition of polymorphic HLA-B molecules. J. Exp. Med. 180:537-43
116. Phillips JH, Gumperz JE, Parham P, Lanier LL. 1995. Superantigen- dependent, cell-mediated cytotoxicity inhibited by MHC class I receptors on T lymphocytes. Science 268:403-5
117. Ferrini S, Cambiaggi A, Meazza R, Sforzini S, Marciano S, et al. 1994. T cell clones expressing the natural killer cell-related p58 receptor molecule display heterogeneity in phenotypic properties and p58 function. Eur. J. Immunol. 24:2294-98
118. Gumperz JE, Valiante NM, Parham P, Lanier LL, Tyan D. 1996. Heterogeneous phenotypes of expression of the NKB1 natural killer cell class I receptor among individuals of different HLA types appear genetically regulated, but not linked to MHC haplotype. J. Exp. Med. 183:1817-27
119. Shilling HG, Young N, Guethlein LA, Cheng NW, Gardiner CM, et al. 2002. Genetic control of human NK cell repertoire. J. Immunol. 169:239-47
120. Santourlidis S, Trompeter HI, Weinhold S, Eisermann B, Meyer KL, et al. 2002. Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells. J. Immunol. 169:4253-61
121. Chan HW, Kurago ZB, Stewart CA, Wilson MJ, Martin MP, et al. 2003. DNA methylation maintains allele-specific KIR gene expression in human natural killer cells. J. Exp. Med. 197:245-55
122. Uhrberg M, Valiante NM, Young NT, Lanier LL, Phillips JH, Parham P. 2001. The repertoire of killer cell Ig-like receptor and CD94:NKG2A receptors in T cells: clones sharing identical αβ TCR rearrangement express highly diverse killer cell Ig-like receptor patterns. J. Immunol. 166:3923-32
123. Vely F, Peyrat MA, Couedel C, Morcet JF, Halary F, et al. 2001. Regulation of inhibitory and activating killer-cell Ig-like receptor expression occurs in T cells after termination of TCR rearrangements. J. Immunol. 166:2487-94
124. + CD28(null) T cells. J. Immunol. 168:3839-46
125. Colonna M, Samaridis J. 1995. Cloning of Ig-superfamily members associated with HLA-C and HLA-B recognition by human NK cells. Science 268:405-8
126. Wagtmann N, Biassoni R, Cantoni C, Verdiani S, Malnati MS, et al. 1995. Molecular clones of the p58 natural killer cell receptor reveal Ig-related molecules with diversity in both the extra- and intracellular domains. Immunity 2:439-49
127. D'Andrea A, Chang C, Franz-Bacon K, McClanahan T, Phillips JH, Lanier LL. 1995. Cutting edge: molecular cloning of NKB1: a natural killer cell receptor for HLA-B allotypes. J. Immunol. 155:2306-10
128. Colonna M, Spies T, Strominger JL, Ciccone E, Moretta A, et al. 1992. Alloantigen recognition by two human natural killer cell clones is associated with HLA-C or a closely linked gene. Proc. Natl. Acad. Sci. USA 89:7983-85
129. Gumperz JE, Litwin V, Phillips JH, Lanier LL, Parham P. 1995. The Bw4 public epitope of HLA-B molecules confers reactivity with NK cell clones that express NKB1, a putative HLA receptor. J. Exp. Med. 181:1133-44
130. Gumperz JE, Barber LD, Valiante NM, Percival L, Phillips JH, et al. 1997. Conserved and variable residues within the Bw4 motif of HLA-B make separable contributions to recognition by the NKB1 killer cell-inhibitory receptor. J. Immunol. 158:5237-41
131. Dohring C, Scheidegger D, Samaridis J, Cella M, Colonna M. 1996. A human killer inhibitory receptor specific for HLA-A. J. Immunol. 156:3098-101
132. Pende D, Biassoni R, Cantoni C, Verdiani S, Falco M, et al. 1996. The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer. J. Exp. Med. 184:505-18
133. Hansasuta P, Dong T, Thananchai H, Weekes M, Willberg C, et al. 2004. Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur. J. Immunol. 34:1673-79
134. Malnati MS, Peruzzi M, Parker KC, Biddison WE, Ciccone E, et al. 1995. Peptide specificity in the recognition of MHC class I by natural killer cell clones. Science 267:1016-18
135. Peruzzi M, Wagtmann N, Long EO. 1996. A p70 killer cell inhibitory receptor specific for several HLA-B allotypes discriminates among peptides bound to HLA-B*2705. J. Exp. Med. 184:1585-90
136. Peruzzi M, Parker KC, Long EO, Malnati MS. 1996. Peptide sequence requirements for the recognition of HLA-B*2705 by specific natural killer cells. J. Immunol. 157:3350-56
137. Gavioli R, Zhang Q-J, Masucci MG. 1996. HLA-A11-mediated protection from NK cell-mediated lysis: role of HLA-A11-presented peptides. Hum. Immunol. 49:1-12
138. Rajagopalan S, Long EO. 1997. The direct binding of a p58 killer cell inhibitory receptor to human histocompatibility leukocyte antigen (HLA)-Cw4 exhibits peptide specificity. J. Exp. Med. 185:1523-28
139. Zappacosta F, Borrego F, Brooks AG, Parker KC, Coligan JE. 1997. Peptides isolated from HLA-CW*0304 confer different degrees of protection from natural killer cell-mediated lysis. Proc. Natl. Acad. Sci. USA 94:6313-18
140. Boyington JC, Motyka SA, Schuck P, Brooks AG, Sun PD. 2000. Crystal structure of an NK cell immunoglobulin-like receptor in complex with its class I MHC ligand. Nature 405:537-43
141. Winter CC, Gumperz JE, Parham P, Long EO, Wagtmann N. 1998. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J. Immunol. 161:571-77
142. Vales-Gomez M, Reyburn HT, Erskine RA, Strominger J. 1998. Differential binding to HLA-C of p50-activating and p58-inhibitory natural killer cell receptors. Proc. Natl. Acad. Sci. USA 95:14326-31
143. Katz G, Markel G, Mizrahi S, Arnon TI, Mandelboim O. 2001. Recognition of HLA-Cw4 but not HLA-Cw6 by the NK cell receptor killer cell Ig-like receptor two-domain short tail number 4. J. Immunol. 166:7260-67
144. Valiante NM, Uhrberg M, Shilling HG, Lienert-Weidenbach K, Arnett KL, et al. 1997. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 7:739-51
145. Stewart CA, Van Bergen J, Trowsdale J. 2003. Different and divergent regulation of the KIR2DL4 and KIR3DL1 promoters. J. Immunol. 170:6073-81
146. Kikuchi-Maki A, Catina TL, Campbell KS. 2004. Structure-function analysis of KIR2DL4: an activating NK cell receptor exhibiting limited expression in humans. Int. Nat. Killer Cell Works., 20th, Abstr. No. B051
147. Selvakumar A, Steffens U, Dupont B. 1996. NK cell receptor gene of the KIR family with two Ig domains but highest homology to KIR receptors with three Ig domains. Tissue Antigens 48:285-95
148. Faure M, Long EO. 2002. KIR2DL4 (CD158d), an NK cell-activating receptor with inhibitory potential. J. Immunol. 168:6208-14
149. Yusa S, Catina TL, Campbell KS. 2002. SHP-1- and phosphotyrosine- independent inhibitory signaling by a killer cell Ig-like receptor cytoplasmic domain in human NK cells. J. Immunol. 168:5047-57
150. Rajagopalan S, Fu J, Long EO. 2001. Cutting edge: induction of IFN-γ production but not cytotoxicity by the killer cell Ig-like receptor KIR2dl4 (CD158d) in resting NK cells. J. Immunol. 167:1877-81
151. Kikuchi-Maki A, Yusa S, Catina TL, Campbell KS. 2003. KIR2DL4 is an IL-2-regulated NK cell receptor that exhibits limited expression in humans but triggers strong IFN-γ production. J. Immunol. 171:3415-25
152. Witt CS, Whiteway JM, Warren HS, Barden A, Rogers M, et al. 2002. Alleles of the KIR2DL4 receptor and their lack of association with pre-eclampsia. Eur. J. Immunol. 32:18-29
153. Rajagopalan S, Long EO. 1999. An HLA-G-specific receptor expressed on all natural killer cells. J. Exp. Med. 189:1093-110
154. Cantoni C, Verdiani S, Falco M, Pessino A, Conte R, et al. 1998. p49, a putative HLA class I-specific inhibitory NK receptor belonging to the immunoglobulin superfamily. Eur. J. Immunol. 28:1980-90
155. Ponte M, Cantoni C, Biassoni R, Tradori-Cappai A, Bentivoglio G, et al. 1999. Inhibitory receptors sensing HLA-G1 molecules in pregnancy: Decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, a novel HLA-G1-specific receptor. Proc. Natl. Acad. Sci. USA 96:5674-79
156. Boyson JE, Erskine R, Whitman MC, Chiu M, Lau JM, et al. 2002. Disulfide bond-mediated dimerization of HLA-G on the cell surface. Proc. Natl. Acad. Sci. USA 99:16180-85
157. Allan DS, Colonna M, Lanier LL, Churakova TD, Abrams JA, et al. 1999. Tetrameric complexes of HLA-G bind to peripheral blood myelomonocytic cells. J. Exp. Med. 189:1149
158. Campbell KS, Dessing M, Lopez-Botet M, Cella M, Colonna M. 1996. Tyrosine phosphorylation of a human killer inhibitory receptor recruits protein tyrosine phosphatase 1C. J. Exp. Med. 184:93-100
159. Burshtyn DN, Scharenberg AM, Wagtmann N, Rajagopalan S, Berrada K, et al. 1996. Recruitment of tyrosine phosphatase HCP by the killer cell inhibitory receptor. Immunity 4:77-85
160. Fry A, Lanier LL, Weiss A. 1996. Phosphotyrosines in the KIR motif of NKB1 are required for negative signaling and for association with PTP1C. J. Exp. Med. 184:295-300
161. Olcese L, Lang P, Vely F, Cambiaggi A, Marguet D, et al. 1996. Human and mouse killer-cell inhibitory receptors recruit PTP1C and PTP1D protein tyrosine phosphatases. J. Immunol. 156:4531-34
162. + T Cells. J. Exp. Med. 197:437-49
163. + CD28null T cells clonally expanded in rheumatoid arthritis. J. Immunol. 165:1138-45
164. Yen JH, Moore BE, Nakajima T, Scholl D, Schaid DJ, et al. 2001. Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J. Exp. Med. 193:1159-68
165. Momot T, Koch S, Hunzelmann N, Krieg T, Ulbricht K, et al. 2004. Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum. 50:1561-65
166. Suzuki Y, Hamamoto Y, Ogasawara Y, Ishikawa K, Yoshikawa Y, et al. 2004. Genetic polymorphisms of killer cell immunoglobulin-like receptors are associated with susceptibility to psoriasis vulgaris. J. Invest. Dermatol. 122:1133-36
167. Mandelboim O, Davis DM, Reyburn HT, Vales-Gomez M, Sheu EG, et al. 1996. Enhancement of class II-restricted T cell responses by costimulatory NK receptors for class I MHC proteins. Science 274:2097-100
168. Flores-Villanueva PO, Yunis EJ, Delgado JC, Vittinghoff E, Buchbinder S, et al. 2001. Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proc. Natl. Acad. Sci. USA 98:5140-45
169. Parham P, McQueen KL. 2003. Alloreactive killer cells: hindrance and help for haematopoietic transplants. Nat. Rev. Immunol. 3:108-22
170. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, et al. 2002. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097-100
171. Bishara A, De Santis D, Witt CC, Brautbar C, Christiansen FT, et al. 2004. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 63:204-11
172. Davies SM, Ruggieri L, DeFor T, Wagner JE, Weisdorf DJ, et al. 2002. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 100:3825-27
173. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, et al. 2003. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102:814-19
174. Houchins JP, Yabe T, McSherry C, Bach FH. 1991. DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. J. Exp. Med. 173:1017-20
175. Chang C, Rodriguez A, Carretero M, Lopez-Botet M, Phillips JH, Lanier LL. 1995. Molecular characterization of human CD94: a type II membrane glycoprotein related to the C-type lectin superfamily. Eur. J. Immunol. 25:2433-37
176. Dissen E, Ber SF, Westgaard IH, Fossum S. 1997. Molecular characterization of a gene in the rat homologous to human CD94. Eur. J. Immunol. 27:2080-86
177. Berg SF, Dissen E, Westgaard IH, Fossum S. 1998. Two genes in the rat homologous to human NKG2. Eur. J. Immunol. 28:444-50
178. Lohwasser S, Hande P, Mager DL, Takei F. 1999. Cloning of murine NKG2A, B and C: second family of C-type lectin receptors on murine NK cells. Eur. J. Immunol. 29:755-61
179. Vance RE, Jamieson AM, Raulet DH. 1999. Recognition of the class Ib molecule Qa-1b by putative activating receptors CD94/NKG2C and CD94/NKG2E on mouse natural killer cells. J. Exp. Med. 190:1801-12
180. Vance RE, Kraft JR, Altman JD, Jensen PE, Raulet DH. 1998. Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) class I molecule Qa-1(b). J Exp. Med. 188:1841-48
181. Shum BP, Flodin LR, Muir DG, Rajalingam R, Khakoo SI, et al. 2002. Conservation and variation in human and common chimpanzee CD94 and NKG2 genes. J. Immunol. 168:240-52
182. Sato A, Mayer WE, Overath P, Klein J. 2003. Genes encoding putative natural killer cell C-type lectin receptors in teleostean fishes. Proc. Natl. Acad. Sci. USA 100:7779-84
183. Khalturin K, Becker M, Rinkevich B, Bosch TC. 2003. Urochordates and the origin of natural killer cells: identification of a CD94/NKR-P1-related receptor in blood cells of Botryllus. Proc. Natl. Acad. Sci. USA 100:622-27
184. Lazetic S, Chang C, Houchins JP, Lanier LL, Phillips JH. 1996. Cutting edge: human NK cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits. J. Immunol. 157:4741-45
185. Brooks AG, Posch PE, Scorzelli CJ, Borrego F, Coligan JE. 1997. NKG2A complexed with CD94 defines a novel inhibitory NK cell receptor. J. Exp. Med. 185:795-800
186. Houchins JP, Lanier LL, Niemi E, Phillips JH, Ryan JC. 1997. Natural killer cell cytolytic activity is inhibited by NKG2-A and activated by NKG2-C. J. Immunol. 158:3603-9
187. Carretero M, Cantoni C, Bellon T, Bottino C, Biassoni R, et al. 1997. The CD94 and NKG2-A C type lectins covalently assemble to form a natural killer cell inhibitory receptor for HLA class I molecules. Eur. J. Immunol. 27:563-75
188. Le Drean E, Vely F, Olcese L, Cambiaggi A, Guia S, et al. 1998. Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatase. Eur. J. Immunol. 28:264-76
189. Lanier LL, Corliss B, Wu J, Phillips JH. 1998. Association of DAP12 with activating CD94/NKG2C NK cell receptors. Immunity 8:693-701
190. Plougastel B, Trowsdale J. 1997. Cloning of NKG2-F, a new member of the NKG2 family of human natural killer cell receptor genes. Eur. J. Immunol. 27:2835-39
191. + T lymphocytes. I. Inhibition of the IL-2 dependent proliferation by anti-Kp43 monoclonal antibody. J. Immunol. 144:3238-47
192. Toyama-Sorimachi N, Taguchi Y, Yagita H, Kitamura F, Kawasaki A, et al. 2001. Mouse CD94 participates in Qa-1-mediated self recognition by NK cells and delivers inhibitory signals independent of Ly-49. J. Immunol. 166:3771-79
193. + Ly-49-cells: a possible mechanism of tolerance during NK cell development. J. Immunol. 162:6976-80
194. Kim S, Iizuka K, Kang HS, Dokun A, French AR, et al. 2002. In vivo developmental stages in murine natural killer cell maturation. Nat. Immunol. 3:523-28
195. Mingari MC, Vitale C, Cantoni C, Bellomo R, Ponte M, et al. 1997. Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2A as the only HLA class I-specific inhibitory receptor. Eur. J. Immunol. 27:1374-80
196. Miller JS, McCullar V. 2001. Human natural killer cells with polyclonal lectin and immunoglobulin-like receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2. Blood 98:705-13
197. + T cells. Proc. Natl. Acad. Sci. USA 95:1172-77
198. Bertone S, Schiavetti F, Bellomo R, Vitale C, Ponte M, Moretta L, Mingari MC. 1999. Transforming growth factor-β-induced expression of CD94/NKG2A inhibitory receptors in human T lymphocytes. Eur. J. Immunol. 29:23-29
199. Derre L, Corvaisier M, Pandolfino MC, Diez E, Jotereau F, Gervois N. 2002. Expression of CD94/NKG2-A on human T lymphocytes is induced by IL-12: implications for adoptive immunotherapy. J. Immunol. 168:4864-70
200. Jabri B, Selby JM, Negulescu H, Lee L, Roberts AI, et al. 2002. TCR specificity dictates CD94/NKG2A expression by human CTL. Immunity 17:487-99
201. Braud VM, Allan DSJ, O'Callaghan CA, Soderstrom K, D'Andrea A, et al. 1998. HLA-E binds to natural killer cell receptors CD94/NKG2A, B, and C. Nature 391:795-98
202. Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG. 1998. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J. Exp. Med. 187:813-18
203. Lee N, Llano M, Carretero M, Ishitani A, Navarro F, et al. 1998. HLA-E is a major ligand for the NK inhibitory receptor CD94/NKG2A. Proc. Natl. Acad. Sci. USA 95:5199-204
204. Aldrich CJ, DeCloux A, Woods AS, Cotter RJ, Soloski MJ, Forman J. 1994. Identification of a TAP-dependent leader peptide recognized by alloreactive T cells specific for a class Ib antigen. Cell 79:649-58
205. Braud V, Jones EY, McMichael A. 1997. The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eur. J. Immunol. 27:1164-69
206. Lee N, Goodlett DR, Ishitani A, Marquardt H, Geraghty DE. 1998. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J. Immunol. 160:4951-60
207. Davies A, Kalb S, Liang B, Aldrich CJ, Lemonnier FA, et al. 2003. A peptide from heat shock protein 60 is the dominant peptide bound to Qa-1 in the absence of the MHC class Ia leader sequence peptide Qdm. J. Immunol. 170:5027-33
208. Miller JD, Weber DA, Ibegbu C, Pohl J, Altman JD, Jensen PE. 2003. Analysis of HLA-E peptide-binding specificity and contact residues in bound peptide required for recognition by CD94/NKG2. J. Immunol. 171:1369-75
209. Valés-Gómez M, Reyburn HT, Erskine RA, Lopez-Botet M, Strominger JL. 1999. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. EMBO J. 18:4250-60
210. Llano M, Lee N, Navarro F, Garcia P, Albar JP, et al. 1998. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur. J. Immunol. 28:2854-63
211. Kraft JR, Vance RE, Pohl J, Martin AM, Raulet DH, Jensen PE. 2000. Analysis of Qa-1(b) peptide binding specificity and the capacity of CD94/NKG2A to discriminate between Qa-1-peptide complexes. J. Exp. Med. 192:613-24
212. Michaelsson J, Teixeira De Matos C, Achour A, Lanier LL, Karre K, Soderstrom K. 2002. A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition. J. Exp. Med. 196:1403-14
213. Tomasec P, Braud VM, Rickards C, Powell MB, McSharry BP, et al. 2000. Surface expression of HLA-E-, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 287:1031-33
214. Ulbrecht M, Martinozzi S, Grzeschik M, Hengel H, Ellwart JW, et al. 2000. Cutting edge: the human cytomegalovirus UL40 gene product contains a ligand for HLA-E and prevents NK cell-mediated lysis. J. Immunol. 164:5019-22
215. Cerboni C, Mousavi-Jazi M, Wakiguchi H, Carbone E, Karre K, Soderstrom K. 2001. Synergistic effect of IFN-γ and human cytomegalovirus protein UL40 in the HLA-E-dependent protection from NK cell-mediated cytotoxicity. Eur. J. Immunol. 31:2926-35
216. Wang EC, McSharry B, Retiere C, Tomasec P, Williams S, et al. 2002. UL40-mediated NK evasion during productive infection with human cytomegalovirus. Proc. Natl. Acad. Sci. USA 99:7570-75
217. + T cell responses. Nat. Immunol. 3:189-95
218. + T cells. J. Immunol. 169:1444-52
219. + T cells. J. Immunol. 169:693-701
220. + T cells. Nat. Immunol. 2:430-35
221. Gunturi A, Berg RE, Forman J. 2003. Preferential survival of CD8 T and NK cells expressing high levels of CD94. J. Immunol. 170:1737-45
222. Cosman D, Fanger N, Borges L, Kibin M, Chin W, et al. 1997. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 7:273-82
223. Colonna M, Navarro F, Bellon T, Llano M, Garcia P, et al. 1997. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J. Exp. Med. 186:1809-18
224. Chapman TL, Heikeman AP, Bjorkman PJ. 1999. The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18. Immunity 11:603-13
225. Lepin EJ, Bastin JM, Allan DS, Roncador G, Braud VM, et al. 2000. Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors. Eur. J. Immunol. 30:3552-61
226. Beck S, Barrell BG. 1988. Human cytomegalovirus encodes a glycoprotein homologous to MHC class-I antigens. Nature 331:269-72
227. Navarro F, Llano M, Bellon T, Colonna M, Geraghty DE, Lopez-Botet M. 1999. The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules coexpressed on target cells. Eur. J. Immunol. 29:277-83
228. Kubagawa H, Burrows PD, Cooper MD. 1997. A novel pair of immunoglobulin-like receptors expressed by B cells and myeloid cells. Proc. Natl. Acad. Sci. USA 94:5261-66
229. Hayami K, Fukuta D, Nishikawa Y, Yamashita Y, Inui M, et al. 1997. Molecular cloning of a novel murine cell-surface glycoprotein homologous to killer cell inhibitory receptors. J. Biol. Chem. 272:7320-27
230. Kubagawa H, Chen CC, Le Hong Ho L, Shimada TS, Gartland L, et al. 1999. Biochemical nature and cellular distribution of the paired immunoglobulin-like receptors, PIR-A and PIR-B. J. Exp. Med. 189:309-18
231. -/- mice. Nat. Immunol. 5:623-29
232. Raulet DH. 2003. Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 3:781-90
233. Ho EL, Carayannopoulos LN, Poursine-Laurent J, Kinder J, Plougastel B, et al. 2002. Costimulation of multiple NK cell activation receptors by NKG2D. J. Immunol. 169:3667-75
234. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, et al. 1999. Activation of natural killer cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727-30
235. Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR, Raulet DH. 2002. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17:19-29
236. Wu J, Song Y, Bakker ABH, Bauer S, Groh V, et al. 1999. An activating receptor complex on natural killer and T cells formed by NKG2D and DAP10. Science 285:730-32
237. Roberts AI, Lee L, Schwarz E, Groh V, Spies T, et al. 2001. Cutting edge: NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J. Immunol. 167:5527-30
238. Sutherland CL, Chalupny NJ, Schooley K, VandenBos T, Kubin M, Cosman D. 2002. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J. Immunol. 168:671-79
239. Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, et al. 2003. Transforming growth factor β 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc. Natl. Acad. Sci. USA 100:4120-25
240. Lee JC, Lee KM, Kim DW, Heo DS. 2004. Elevated TGF-β1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J. Immunol. 172:7335-40
241. Diefenbach A, Tomasello E, Lucas M, Jamieson AM, Hsia JK, et al. 2002. Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat. Immunol. 3:1142-49
242. Gilfillan S, Ho EL, Cella M, Yokoyama WM, Colonna M. 2002. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nat. Immunol. 3:1150-55
243. Wu J, Cherwinski H, Spies T, Phillips JH, Lanier LL. 2000. DAP10 and DAP12 form distinct, but functionally cooperative, receptor complexes in natural killer cells. J. Exp. Med. 192:1059-68
244. Andre P, Castriconi R, Espeli M, Anfossi N, Juarez T, et al. 2004. Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors. Eur. J. Immunol. 34:961-71.
245. Billadeau DD, Upshaw JL, Schoon RA, Dick CJ, Leibson PJ. 2003. NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. Nat. Immunol. 4:557-64
246. Rosen DB, Araki M, Hamerman JA, Chen T, Yamamura T, Lanier LL. 2004. A structural basis for the association of DAP12 with mouse, but not human, NKG2D. J. Immunol. 173:2470-78
247. Radaev S, Sun PD. 2003. Structure and function of natural killer cell surface receptors. Annu. Rev. Biophys. Biomol. Struct. 32:93-114
248. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, et al. 2001. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14:123-33
249. Jan Chalupny N, Sutherland CL, Lawrence WA, Rein-Weston A, Cosman D. 2003. ULBP4 is a novel ligand for human NKG2D. Biochem. Biophys. Res. Commun. 305:129-35
250. Cerwenka A, Bakker AB, McClanahan T, Wagner J, Wu J, et al. 2000. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 12:721-27
251. Carayannopoulos LN, Naidenko OV, Fremont DH, Yokoyama WM. 2002. Cutting edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D. J. Immunol. 169:4079-83
252. Diefenbach A, Hsia JK, Hsiung MY, Raulet DH. 2003. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity. Eur. J. Immunol. 33:381-91
253. Bahram S, Bresnahan M, Geraghty DE, Spies T. 1994. A second lineage of mammalian major histocompatibility complex class I genes. Proc. Natl. Acad. Sci. USA 91:6259-63
254. Radosavljevic M, Cuillerier B, Wilson MJ, Clement O, Wicker S, et al. 2002. A cluster of ten novel MHC class I related genes on human chromosome 6q24.2-q25.3. Genomics 79:114-23
255. Li P, Morris DL, Willcox BE, Steinle A, Spies T, Strong RK. 2001. Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Nat. Immunol. 2:443-51
256. Li P, McDermott G, Strong RK. 2002. Crystal structures of RAE-1β and its complex with the activating immunoreceptor NKG2D. Immunity 16:77-86
257. Holmes MA, Li P, Petersdorf EW, Strong RK. 2002. Structural studies of allelic diversity of the MHC class I homolog MIC-B, a stress-inducible ligand for the activating immunoreceptor NKG2D. J. Immunol. 169:1395-400
258. Radaev S, Rostro B, Brooks AG, Colonna M, Sun PD. 2001. Conformational plasticity revealed by the cocrystal structure of NKG2D and its class I MHC-like ligand ULBP3. Immunity 15:1039-49
259. Li P, Willie ST, Bauer S, Morris DL, Spies T, Strong RK. 1999. Crystal structure of the MHC class I homolog MIC-A, a γδ T cell ligand. Immunity 10:577-84
260. Li Z, Groh V, Strong RK, Spies T. 2000. A single amino acid substitution causes loss of expression of a MICA allele. Immunogenetics 51:246-48
261. Steinle A, Li P, Morris DL, Groh V, Lanier LL, Strong RK, Spies T. 2001. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics 53:279-87
262. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. 1996. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc. Natl. Acad. Sci. USA 93:12445-50
263. Nomura M, Zou Z, Joh T, Takihara Y, Matsuda Y, Shimada K. 1996. Genomic structures and characterization of Rae1 family members encoding GPI-anchored cell surface proteins and expressed predominantly in embryonic mouse brain. J. Biochem. 120:987-95
264. Zou Z, Nomura M, Takihara Y, Yasunaga T, Shimada K. 1996. Isolation and characterization of retinoic acid-inducible cDNA clones in F9 cells: a novel cDNA family encodes cell surface proteins sharing partial homology with MHC class I molecules. J. Biochem. 119:319-28
265. Hamerman JA, Ogasawara K, Lanier LL. 2004. Cutting edge: Toll-like receptor signaling in macrophages induces ligands for the NKG2D receptor. J. Immunol. 172:2001-5
266. Lodoen M, Ogasawara K, Hamerman JA, Arase H, Houchins JP, et al. 2003. NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules. J. Exp. Med. 197:1245-53
267. + T cell pathway. J. Immunol. 172:757-61
268. Wu J, Chalupny NJ, Manley TJ, Riddell SR, Cosman D, Spies T. 2003. Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein. J. Immunol. 170:4196-200
269. Welte SA, Sinzger C, Lutz SZ, Singh-Jasuja H, Sampaio KL, et al. 2003. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur. J. Immunol. 33:194-203
270. Dunn C, Chalupny NJ, Sutherland CL, Dosch S, Sivakumar PV, et al. 2003. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. J. Exp. Med. 197:1427-39
271. Rolle A, Mousavi-Jazi M, Eriksson M, Odeberg J, Soderberg-Naucler C, et al. 2003. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein. J. Immunol. 171:902-8
272. Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T. 2001. Costimulation of CD8αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat. Immunol. 2:255-60
273. + T cells and NK cells in vivo. Nat. Immunol. 3:529-35
274. Lodoen M, Abenes G, Umamoto S, Houchins JP, Li F, Lanier LL. 2004. The cytomegalovirus m155 gene product subverts NK cell antiviral protection by disruption of H60-NKG2D interactions. J. Exp. Med. 200:1075-81
275. Ziegler H, Thale R, Lucin P, Muranyi W, Flohr T, et al. 1997. A mouse cytomegalovirus glycoprotein retains MHC class I complexes in the ERGIC/cis-Golgi compartments. Immunity 6:57-66
276. Abenes G, Chan K, Lee M, Haghjoo E, Zhu J, et al. 2004. Murine cytomegalovirus with a transposon insertional mutation at open reading frame m155 is deficient in growth and virulence in mice. J. Virol. 78:6891-99
277. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. 1999. Broad tumor-associated expression and recognition by tumor-derived γδ cells of MICA and MICB. Proc. Natl. Acad. Sci. USA 96:6879-84
278. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. 2000. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat. Immunol. 1:119-26
279. Groh V, Wu J, Yee C, Spies T. 2002. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734-38
280. Doubrovina ES, Doubrovin MM, Vider E, Sisson RB, O'Reilly RJ, et al. 2003. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J. Immunol. 171:6891-99
281. Salih HR, Rammensee HG, Steinle A. 2002. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J. Immunol. 169:4098-102
282. Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T. 2003. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 100:9452-57
283. Ogasawara K, Hamerman JA, Ehrlich LR, Bour-Jordan H, Santamaria P, et al. 2004. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity 20:757-67
284. Poirot L, Benoist C, Mathis D. 2004. Natural killer cells distinguish innocuous and destructive forms of pancreatic islet autoimmunity. Proc. Natl. Acad. Sci. USA 101:8102-7
285. Glimcher L, Shen FW, Cantor H. 1977. Identification of a cell-surface antigen selectively expressed on the natural killer cell. J. Exp. Med. 145:1-9
286. Yokoyama WM, Ryan JC, Hunter JJ, Smith HRC, Stark M, Seaman WE. 1991. cDNA cloning of mouse NKR-P1 and genetic linkage with Ly-49: identification of a natural killer cell gene complex on mouse chromosome 6. J. Immunol. 147:3229-36
287. Giorda R, Weisberg EP, Ip TK, Trucco M. 1992. Genomic structure and strain-specific expression of the natural killer cell receptor NKR-P1. J. Immunol. 149:1957-63
288. Ryan JC, Turck J, Niemi EC, Yokoyama WM, Seaman WE. 1992. Molecular cloning of the NK1.1 antigen, a member of the NKR-P1 family of natural killer cell activation molecules. J. Immunol. 149:1631-35
289. Giorda R, Rudert WA, Vavassori C, Chambers WH, Hiserodt JC, Trucco M. 1990. NKR-P1, a signal transduction molecule on natural killer cells. Science 249:1298-300
290. Lanier LL, Chang C, Phillips JH. 1994. Human NKR-P1A: a disulfide linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes. J. Immunol. 153:2417-28
291. Koo GC, Peppard JR. 1984. Establishment of monoclonal anti-NK1.1 antibody. Hybridoma 3:301
292. Carlyle JR, Martin A, Mehra A, Attisano L, Tsui FW, Zuniga-Pflucker JC. 1999. Mouse NKR-P1B, a novel NK1.1 antigen with inhibitory function. J. Immunol. 162:5917-23
293. + T cells upon NKR-P1 cross-linking. J. Exp. Med. 183:2391-96
294. + T cells. J. Exp. Med. 186:1957-63
295. + T lymphocytes. Science 268:863-65
296. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. 2000. NKT cells: facts, functions and fallacies. Immunol. Today 21:573-83
297. Plougastel B, Dubbelde C, Yokoyama WM. 2001. Cloning of Clr, a new family of lectin-like genes localized between mouse Nkrp1a and Cd69. Immunogenetics 53:209-14
298. Zhou H, Kartsogiannis V, Hu YS, Elliott J, Quinn JM, et al. 2001. A novel osteoblast-derived C-type lectin that inhibits osteoclast formation. J. Biol. Chem. 276:14916-23
299. Hu YS, Zhou H, Myers D, Quinn JM, Atkins GJ, et al. 2004. Isolation of a human homolog of osteoclast inhibitory lectin that inhibits the formation and function of osteoclasts. J. Bone Miner. Res. 19:89-99
300. Mocsai A, Humphrey MB, Van Ziffle JA, Hu Y, Burghardt A, et al. 2004. The immunomodulatory adapter proteins DAP12 and Fc receptor γ-chain (FcRγ) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc. Natl. Acad. Sci. USA 101:6158-63
301. Koga T, Inui M, Inoue K, Kim S, Suematsu A, et al. 2004. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428:758-63
302. Boles KS, Barten R, Kumaresan PR, Trowsdale J, Mathew PA. 1999. Cloning of a new lectin-like receptor expressed on human NK cells. Immunogenetics 50:1-7
303. Mathew PA, Chuang SS, Vaidya SV, Kumaresan PR, Boles KS, Pham HT. 2004. The LLT1 receptor induces IFN-γ production by human natural killer cells. Mol. Immunol. 40:1157-63
304. Exley M, Porcelli S, Furman M, Garcia J, Balk S. 1998. CD161 (NKR-P1A) costimulation of CD1d-dependent activation of human T cells expressing invariant Vα24JαQ T cell receptor α chains. J. Exp. Med. 188:867-76
305. + human T lymphocytes. Immunol. Lett 57:121-23
306. + immature thymocytes: NKRP1A-mediated regulation of proliferation and cytolytic activity. Eur. J. Immunol. 26:12660-72
307. Brown MH, Boles K, Anton van der Merwe P, Kumar V, Mathew PA, Barclay NA. 1998. 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48. J. Exp. Med. 188:2083-90
308. Latchman Y, McKay PF, Reiser H. 1998. Identification of the 2B4 molecule as a counter-receptor for CD48. J. Immunol. 161:5809-12
309. Garni-Wagner BA, Purohit A, Mathew PA, Bennett M, Kumar K. 1993. A novel function-associated molecule related to non-MHC-restricted cytotoxicity mediated by activated natural killer cells and T cells. J. Immunol. 151:60-70
310. Valiante NM, Trinchieri G. 1993. Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes. J. Exp. Med. 178:1397-406
311. Mathew PA, Garni-Wagner BA, Land K, Takashima A, Stoneman E, et al. 1993. Cloning and characterization of the 2B4 gene encoding a molecule associated with non-MHC-restricted killing mediated by activated natural killer cells and T cells. J. Immunol. 151:5328-37
312. Boles KS, Nakajima H, Colonna M, Chuang SS, Stepp SE, et al. 1999. Molecular characterization of a novel human natural killer cell receptor homologous to mouse 2B4. Tissue Antigens 54:27-34
313. Tangye SG, Lazetic S, Woollatt E, Sutherland GR, Lanier LL, Phillips JH. 1999. Cutting Edge: human 2B4, an activating NK cell receptor, recruits the protein tyrosine phosphatase SHP-2 and the adaptor signaling protein SAP. J. Immunol. 162:6981-85
314. Kubin MZ, Parshley DL, Din W, Waugh JY, Davis-Smith T, et al. 1999. Molecular cloning and biological characterization of NK cell activation-inducing ligand, a counterstructure for CD48. Eur. J. Immunol. 29:3466-77
315. Nakajima H, Cella M, Langen H, Friedlein A, Colonna M. 1999. Activating interactions in human NK cell recognition: the role of 2B4-CD48. Eur. J. Immunol. 29:1676-83
316. + effector αβ T cells. J. Immunol. 167:6165-70
317. + T cells in HIV-1-infected patients with progressing disease. J. Immunol. 162:7563-68
318. Engel P, Eck MJ, Terhorst C. 2003. The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease. Nat. Rev. Immunol. 3:813-21
319. Bottino C, Falco M, Parolini S, Marcenaro E, Augugliaro R, et al. 2001. Ntb-a, a novel sh2dla-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in x-linked lymphoproliferative disease. J. Exp. Med. 194:235-46
320. Bouchon A, Cella M, Grierson HL, Cohen JI, Colonna M. 2001. Cutting edge: activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family. J. Immunol. 167:5517-21
321. Parolini S, Bottino C, Falco M, Augugliaro R, Giliani S, et al. 2000. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J. Exp. Med. 192:337-46
322. Nakajima H, Cella M, Bouchon A, Grierson HL, Lewis J, et al. 2000. Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity. Eur. J. Immunol. 30:3309-18
323. Schatzle JD, Sheu S, Stepp SE, Mathew PA, Bennett M, Kumar V. 1999. Characterization of inhibitory and stimulatory forms of the murine natural killer cell receptor 2B4. Proc. Natl. Acad. Sci. USA 96:3870-75
324. Chen R, Relouzat F, Roncagalli R, Aoukaty A, Tan R, et al. 2004. Molecular dissection of 2B4 signaling: implications for signal transduction by SLAM-related receptors. Mol. Cell Biol. 24:5144-56
325. Bottino C, Augugliaro R, Castriconi R, Nanni M, Biassoni R, et al. 2000. Analysis of the molecular mechanism involved in 2B4-mediated NK cell activation: evidence that human 2B4 is physically and functionally associated with the linker for activation of T cells. Eur. J. Immunol. 30:3718-22
326. Riteau B, Barber DF, Long EO. 2003. Vav1 phosphorylation is induced by β2 integrin engagement on natural killer cells upstream of actin cytoskeleton and lipid raft reorganization. J. Exp. Med. 198:469-74
327. Klem J, Verrett PC, Kumar V, Schatzle JD. 2002. 2B4 is constitutively associated with linker for the activation of T cells in glycolipid-enriched microdomains: properties required for 2B4 lytic function. J. Immunol. 169:55-62
328. Lee KM, McNerney ME, Stepp SE, Mathew PA, Schatzle JD, et al. 2004. 2B4 Acts as a non-major histocompatibility complex binding inhibitory receptor on mouse natural killer cells. J. Exp. Med. 199:1245-54
329. Sivori S, Parolini S, Falco M, Marcenaro E, Biassoni R, et al. 2000. 2B4 functions as a co-receptor in human NK cell activation. Eur. J. Immunol. 30:787-93
330. Tangye SG, Phillips JH, Lanier LL. 2000. The CD2-subset of the Ig superfamily of cell surface molecules: receptor-ligand pairs expressed by NK cells and other immune cells. Semin. Immunol. 12:149-57
331. Tangye SG, Phillips JH, Lanier LL, Nichols KE. 2000. Cutting Edge: functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome. J. Immunol. 165:2932-36
332. Benoit L, Wang X, Pabst HF, Dutz J, Tan R. 2000. Defective NK cell activation in X-linked lymphoproliferative disease. J. Immunol. 165:3549-53
333. Sivori S, Falco M, Marcenaro E, Parolini S, Biassoni R, et al. 2002. Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation. Proc. Natl. Acad. Sci. USA 99:4526-31
334. Burns GF, Triglia T, Werkmeister JA, Begley CG, Boyd AW. 1985. TLiSA1, a human T lineage-specific activation antigen involved in the differentiation of cytotoxic T lymphocytes and anomalous killer cells from their precursors. J. Exp. Med. 161:1063-78
335. Scott JL, Dunn SM, Hillam AJ, Walton S, Berndt MC, et al. 1989. Characterization of a novel membrane glycoprotein involved in platelet activation. J. Biol. Chem. 264:13475-82
336. Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, et al. 1996. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 4:573-81
337. Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, et al. 2003. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J. Exp. Med. 198:557-67
338. Tahara-Hanaoka S, Shibuya K, Onoda Y, Zhang H, Yamazaki S, et al. 2004. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). Int. Immunol. 16:533-38
339. Masson D, Jarry A, Baury B, Blanchardie P, Laboisse C, et al. 2001. Overexpression of the CD155 gene in human colorectal carcinoma. Gut 49:236-40
340. Shibuya K, Lanier LL, Phillips JH, Ochs HD, Shimizu K, et al. 1999. Physical and functional association of LFA-1 with DNAM-1 adhesion molecule. Immunity 11:615-23
341. Shibuya K, Shirakawa J, Kameyama T, Honda S, Tahara-Hanaoka S, et al. 2003. CD226 (DNAM-1) is involved in lymphocyte function-associated antigen 1 costimulatory signal for naive T cell differentiation and proliferation. J. Exp. Med. 198:1829-39
342. Reymond N, Imbert AM, Devilard E, Fabre S, Chabannon C, et al. 2004. DNAM-1 and PVR regulate monocyte migration through endothelial junctions. J. Exp. Med. 199:1331-41
343. Fuchs A, Cella M, Giurisato E, Shaw AS, Colonna M. 2004. Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155). J. Immunol. 172:3994-98
344. Shiratori I, Ogasawara K, Saito T, Lanier LL, Arase H. 2004. Activation of natural killer cells and dendritic cells upon recognition of a novel CD99-like ligand by paired immunoglobulin-like Type 2 receptor. J. Exp. Med. 199:525-33
345. Mousseau DD, Banville D, L'Abbe D, Bouchard P, Shen S-H. 2000. PILRα, a novel immunoreceptor tyrosine-based inhibitory motif-bearing protein, recruits SHP-1 upon tyrosine phosphorylation and is paired with the truncated counterpart PILRβ. J. Biol. Chem. 275:4467-74
346. Fournier N, Chalus L, Durand I, Garcia E, Pin JJ, et al. 2000. FDF03, a novel inhibitory receptor of the immunoglobulin superfamily, is expressed by human dendritic and myeloid cells. J. Immunol. 165:1197-209
347. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, et al. 2001. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19:197-223
348. Pende D, Parolini S, Pessino A, Sivori S, Augugliaro R, et al. 1999. Identification and molecular characterization of NKP30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J. Exp. Med. 190:1505-16
349. Nalabolu SR, Shukla H, Nallur G, Parimoo S, Weissman SM. 1996. Genes in a 220-kb region spanning the TNF cluster in human MHC. Genomics 31:215-22
350. Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, et al. 1998. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J. Exp. Med. 187:2065-72
351. Cantoni C, Bottino C, Vitale M, Pessino A, Augugliaro R, et al. 1999. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J. Exp. Med. 189:787-96
352. Pessino A, Sivori S, Bottino C, Malaspina A, Morelli L, et al. 1998. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J. Exp. Med. 188:953-60